Oxford Bioscience Partners - Boston, MA
|
Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance to emerging, entrepreneurial-driven companies within the life sciences and healthcare sectors. Experienced partners, who bring together deep domain knowledge in life sciences, have established a proven track record of identifying, validating and backing emerging trends and technologies. While willing to consider an investment in a company at almost any stage, OBP brings unique value and expertise to early-stage situations. With approximately $1B of committed capital under management, OBP has invested in over 140 life science companies worldwide, and has successfully leveraged the extensive research, operating, and financial expertise and experience of its team of investment professionals.
Oxford's team of investment professionals has a history of backing leading life science companies, including: SIRNA (acquired by Merck); SOLEXA (acquired by Illumina); ALANTOS (acquired by Amgen); TRUBION (NASDAQ: TRBN); HYPNION (acquired by Eli Lilly); HUMAN GENOME SCIENCES (NASDAQ: HGSI); POWDERMED (acquired by Pfizer); ACADIA (NASDAQ; ACAD); PVT (acquired by Edwards); EXELIXIS (NASDAQ: EXEL); SOSEI (Nikkei: 4565); COHESIVE (acquired by Thermo Fisher); IMPELLA (acquired by Abiomed); STRATAGENE (acquired by Agilent); SANTHERA (SWX:SANN); EXONHIT (EURONEXT: ALEHT); INVERNESS MEDICAL (NYSE: IMA)
|
| |
|
|
 |
|
|
 |
|
October 23, 2008
Advisory Board Meetings
@ Oxford Bioscience Partners
222 Berkeley Street, Suite 1650
Boston, MA 02116
October 24, 2008
Annual Limited Partners Meeting
@ Four Seasons Hotel
200 Boylston Street
Boston, MA 02116
September 19, 2007
Oxford Bioscience Partners Promotes Dr. Douglas Fambrough to General Partner
July 6, 2007
Oxford Bioscience Keeps Successes on the QT
August 25, 2008
AVEO Initiates Phase 1b Combination Trial of AV-951 with FOLFOX6 in Patients with Advanced Colorectal and Other Gastrointestinal Cancers --
moreAugust 22, 2008
Santhera's 2008 Interim Results Reflect Advances in Clinical Development and Preparation for First Product Launch --
moreAugust 21, 2008
VaxInnate's M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study --
moreAugust 15, 2008
Santhera's Omigapil Receives Orphan Drug Designation from FDA and EMEA --
moreAugust 11, 2008
Cardiome and Astellas Announce Receipt of FDA Approvable Letter for KYNAPID --
moreAugust 8, 2008
Santhera Provides Update on Clinical/Regulatory Processes with SNT-MC17/Idebenone for the Treatment of Friedreich's Ataxia --
moreJuly 30, 2008
Memory Pharmaceuticals Presents Positive Preclinical Data for MEM 68626 at ICAD 2008 --
moreJuly 24, 2008
Santhera Receives First Product Approval: Health Canada Approves Catena® for Treatment of Friedreich's Ataxia --
more
|
|
|
|